NEW YORK (GenomeWeb) – Cancer genetics testing firm NeoGenomics today announced Aurora Diagnostics has selected it to be the primary partner for molecular testing in Aurora's US network of specialized pathology laboratories.

Aurora will be able to standardize oncology molecular testing services across its 19 labs as a result of the deal, NeoGenomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.